9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Interleukin-12 in Treating Patients With Cancer in the Abdomen

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Estimated reading time: < 1 min

Condition: Anal Cancer

Estimated Enrollment: 29

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12,  ,  ,

Interventions: Recombinant Interleukin-12,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: October 2001

Completion Date: October 2001

Last  Posted Date: July 30, 2012

Location: University of Texas – MD Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT00003046

Was this article helpful?
Dislike 0